US Patent Issued to DANA-FARBER CANCER INSTITUTE, THE BRIGHAM AND WOMEN'S HOSPITAL on Feb. 24 for "Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,559, issued on Feb. 24, was assigned to DANA-FARBER CANCER INSTITUTE INC. (Boston) and THE BRIGHAM AND WOMEN'S HOSPITAL INC. (Boston).

"Targeting Galectin-9 as a therapeutic strategy for T-cell exhaustion in T-cell acute lymphoblastic leukemia" was invented by Birgit Knoechel (Brookline, Mass.), Jens G. Lohr (Brookline, Mass.), Praveen Anand (Allston, Mass.), Amy Guillaumet-Adkins (Allston, Mass.) and Jon Aster (Lexington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to compositions and methods for treating early T-cell precursor acute lymphoblastic leukemia (ETP T-ALL)."

The patent was filed on July 10, 2020, ...